ProCE Banner Activity

Key Updates in HCC Treatment From ASCO GI 2021

Clinical Thought
With this commentary, review expert discussion of key studies in HCC presented as ASCO GI 2021, with a focus on potentially practice-changing data.

Released: February 11, 2021

Expiration: February 10, 2022

Share

Faculty

Mark Yarchoan

Mark Yarchoan, MD

Associate Professor of Medical Oncology
Division of GI Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Genentech, a member of the Roche Group

Lilly

Faculty Disclosure

Primary Author

Mark Yarchoan, MD

Associate Professor of Medical Oncology
Division of GI Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Mark Yarchoan, MD, has disclosed that he has received consulting fees from AstraZeneca, Eisai, Exelixis, and Genentech.